Kinnate Biopharma Probability of Future Stock Price Finishing Under 3.23
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
Kinnate |
Kinnate Biopharma Target Price Odds to finish below 3.23
The tendency of Kinnate Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 3.23 after 90 days |
| 2.96 | 90 days | 3.23 | about 40.22 |
Based on a normal probability distribution, the odds of Kinnate Biopharma to stay under $ 3.23 after 90 days from now is about 40.22 (This Kinnate Biopharma probability density function shows the probability of Kinnate Stock to fall within a particular range of prices over 90 days) . Probability of Kinnate Biopharma price to stay between its current price of $ 2.96 and $ 3.23 at the end of the 90-day period is about 19.02 .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.2 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Kinnate Biopharma will likely underperform. Additionally Kinnate Biopharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Kinnate Biopharma Price Density |
| Price |
Predictive Modules for Kinnate Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Kinnate Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kinnate Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Kinnate Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Kinnate Biopharma is not an exception. The market had few large corrections towards the Kinnate Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Kinnate Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Kinnate Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.09 | |
β | Beta against Dow Jones | 2.20 | |
σ | Overall volatility | 0.49 | |
Ir | Information ratio | -0.01 |
Kinnate Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Kinnate Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Kinnate Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Kinnate Biopharma is not yet fully synchronised with the market data | |
| Kinnate Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (112.65 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kinnate Biopharma currently holds about 262.42 M in cash with (100.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 83.0% of the company shares are owned by institutional investors |
Kinnate Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Kinnate Stock often depends not only on the future outlook of the current and potential Kinnate Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Kinnate Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 46.6 M | |
| Cash And Short Term Investments | 154 M |
Kinnate Biopharma Technical Analysis
Kinnate Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Kinnate Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Kinnate Biopharma. In general, you should focus on analyzing Kinnate Stock price patterns and their correlations with different microeconomic environments and drivers.
Kinnate Biopharma Predictive Forecast Models
Kinnate Biopharma's time-series forecasting models is one of many Kinnate Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Kinnate Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Kinnate Biopharma
Checking the ongoing alerts about Kinnate Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Kinnate Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Kinnate Biopharma is not yet fully synchronised with the market data | |
| Kinnate Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (112.65 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kinnate Biopharma currently holds about 262.42 M in cash with (100.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 83.0% of the company shares are owned by institutional investors |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |